PFN1 — Profilin 1

PFN1 — Profilin 1

Overview

PFN1 encodes profilin 1, a small 15-kDa actin-binding protein that regulates actin polymerization and depolymerization. Profilin 1 is essential for cytoskeletal dynamics, cellular motility, synaptic function, and numerous cellular processes. As a fundamental regulator of the actin cytoskeleton, PFN1 plays critical roles in neuronal morphogenesis, axonal guidance, dendritic spine formation, and synaptic plasticity.

The discovery of PFN1 mutations in familial amyotrophic lateral sclerosis (ALS) in 2012 established cytoskeletal dysfunction as a key pathway in motor neuron disease[@wu2012]. Since then, research has revealed that PFN1 mutations cause ALS through multiple pathogenic mechanisms including disrupted actin dynamics, impaired autophagy, mitochondrial dysfunction, and altered RNA granule trafficking. Beyond ALS, PFN1 has been implicated in frontotemporal dementia (FTD), Parkinson's disease, and Charcot-Marie-Tooth disease, highlighting its importance in broader neurodegenerative processes[@aladesuyi2023].

PFN1 — Profilin 1

Overview

PFN1 encodes profilin 1, a small 15-kDa actin-binding protein that regulates actin polymerization and depolymerization. Profilin 1 is essential for cytoskeletal dynamics, cellular motility, synaptic function, and numerous cellular processes. As a fundamental regulator of the actin cytoskeleton, PFN1 plays critical roles in neuronal morphogenesis, axonal guidance, dendritic spine formation, and synaptic plasticity.

The discovery of PFN1 mutations in familial amyotrophic lateral sclerosis (ALS) in 2012 established cytoskeletal dysfunction as a key pathway in motor neuron disease[@wu2012]. Since then, research has revealed that PFN1 mutations cause ALS through multiple pathogenic mechanisms including disrupted actin dynamics, impaired autophagy, mitochondrial dysfunction, and altered RNA granule trafficking. Beyond ALS, PFN1 has been implicated in frontotemporal dementia (FTD), Parkinson's disease, and Charcot-Marie-Tooth disease, highlighting its importance in broader neurodegenerative processes[@aladesuyi2023].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Profilin 1 (PFN1)</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>PFN1</td></tr>
<tr><td><strong>Protein Name</strong></td><td>Profilin-1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>17p13.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[5216](https://www.ncbi.nlm.nih.gov/gene/5216)</td></tr>
<tr><td><strong>OMIM</strong></td><td>176610</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000108518</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P07737](https://www.uniprot.org/uniprot/P07737)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Profilin family</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Cytoplasm, membrane-associated</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>ALS, FTD, PD, Charcot-Marie-Tooth</td></tr>
</table>
</div>

Gene and Protein Structure

Genomic Organization

The PFN1 gene is located on chromosome 17p13.3 and spans approximately 4.5 kb of genomic DNA. The gene consists of 4 exons that encode a protein of 140 amino acids with a molecular weight of approximately 15 kDa. The gene promoter contains multiple regulatory elements including GC-rich regions and transcription factor binding sites that enable tissue-specific expression[@wu2012].

Protein Structure

Profilin 1 adopts a compact globular structure composed of:

The protein contains two major binding interfaces:

• Actin-binding site: Interacts with G-actin (monomeric actin)
• Polyproline binding site: Binds to proline-rich sequences in various proteins

Biological Functions

Actin Dynamics Regulation

Profilin 1 is a fundamental regulator of actin dynamics through multiple mechanisms[@pun2019]:

Cellular Functions

Beyond actin regulation, profilin 1 participates in:

• Cytoskeletal organization: Maintains cell shape and structure
• Cell migration: Essential for lamellipodia and filopodia formation
• Neuronal morphogenesis: Guides axon outgrowth and branching
• Synaptic plasticity: Regulates dendritic spine dynamics
• Axonal guidance: Mediates growth cone responses
• Endocytosis: Participates in membrane trafficking

Protein Interactions

Profilin 1 interacts with numerous cellular proteins:

| Partner | Function |
|---------|----------|
| G-actin | Actin dynamics |
| Polyproline proteins | Diverse signaling |
| PLD (phospholipase D) | Membrane trafficking |
| Rho GTPases | Cytoskeletal regulation |
| VASP | Cytoskeletal assembly |
| Ena/VASP proteins | Filopodia formation |
| Formins | Actin polymerization |

Expression Pattern

Tissue Distribution

Profilin 1 is ubiquitously expressed with highest levels in:

• Brain: Cerebral cortex, hippocampus, spinal cord motor neurons
• Muscle: Skeletal muscle, cardiac muscle
• Testis: Spermatogenesis
• Platelets: Cytoskeletal function

Brain Expression

Within the brain, PFN1 shows distinctive patterns:

• Motor neurons: High expression in spinal cord and brainstem
• Cortical neurons: Pyramidal neurons in layers 2/3 and 5
• Hippocampal neurons: CA1-CA3 pyramidal cells, dentate gyrus
• Synaptic terminals: Enriched in presynaptic and postsynaptic compartments

Subcellular Localization

• Cytoplasm: Primary location
• Growth cones: Essential for axonal guidance
• Dendritic spines: Synaptic plasticity regulation
• Membrane: Dynamic membrane association
• Mitochondria: Implicated in mitochondrial function

Role in Amyotrophic Lateral Sclerosis

Discovery and Genetics

PFN1 was first linked to familial ALS in 2012 when exome sequencing identified pathogenic mutations in affected families[@wu2012]. Since then, multiple PFN1 mutations have been identified:

| Mutation | Location | Pathogenic Evidence |
|----------|----------|-------------------|
| C71G | Exon 2 | Segregates with disease |
| M114T | Exon 3 | In vitro functional assays |
| G118V | Exon 3 | Segregates with disease |
| E117D | Exon 3 | Variable penetrance |
| A92T | Exon 2 | Reported in families |

PFN1 mutations account for approximately 1-2% of familial ALS cases and demonstrate autosomal dominant inheritance with variable expressivity[@smith2013].

Pathogenic Mechanisms

PFN1 mutations cause ALS through multiple interconnected mechanisms[@aladesuyi2023][@fil2017]:

• Impaired actin polymerization
• Defective axonal transport
• Aberrant growth cone morphology
• Reduced dendritic spine formation

• Profilin mutants show accumulation of autophagic vacuoles
• Disrupted mitophagy
• Accumulation of protein aggregates

• Altered mitochondrial distribution
• Impaired mitochondrial transport
• Reduced mitochondrial membrane potential
• Enhanced susceptibility to stress

• Disrupted stress granule dynamics
• Altered mRNA localization
• Impaired RNA quality control

• PFN1 mutants form cytoplasmic aggregates
• Sequestration of wild-type PFN1
• Toxic gain of function["@march2016"]

Animal Models

| Model | Modification | Phenotype |
|-------|-------------|-----------|
| PFN1 knockout | Deletion | Embryonic lethal |
| PFN1 knockin (C71G) | Point mutation | ALS-like phenotype |
| PFN1 knockin (G118V) | Point mutation | Motor neuron degeneration |
| Motor neuron-specific KO | Conditional | Progressive weakness |

Role in Frontotemporal Dementia

PFN1 mutations have also been identified in FTD cases, establishing a link between cytoskeletal dysfunction and FTD spectrum disorders[@boeddinghaus2020]:

• PFN1 variants found in FTD patients without ALS
• Overlapping pathogenic mechanisms with ALS
• Possible genetic interaction with other FTD genes (C9orf72, MAPT, GRN)
• Shared cytoskeletal dysfunction pathway

Role in Parkinson's Disease

In Parkinson's disease, profilin 1 plays roles in:

Therapeutic Implications

Therapeutic Strategies

| Strategy | Approach | Development Status |
|----------|----------|-------------------|
| Gene therapy | AAV-PFN1 delivery | Preclinical |
| Actin modulators | Small molecules targeting actin dynamics | Research |
| Autophagy enhancers | mTOR inhibitors, rapamycin | Research |
| Mitochondrial protectants | CoQ10, idebenone | Research |
| Protein aggregation inhibitors | Compound screening | Preclinical |

Drug Development

Recent efforts have focused on developing actin-targeting compounds for ALS[@deng2022][@schwab2018]:

• Profilin-actin stabilizers: Promote proper actin function
• Autophagy inducers: Enhance clearance of aggregates
• Mitochondrial protectors: Improve energy metabolism
• Aggregate breakers: Disrupt toxic protein assemblies

CRISPR Screening

Recent genetic screens have identified PFN1 synthetic lethal partners[@liu2023]:

• Genes in actin regulatory pathways
• Autophagy-related genes
• Mitochondrial quality control genes
• Potential therapeutic targets

Cross-Links

PFN1 connects to multiple NeuroWiki pages:

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Cytoskeletal Dynamics](/mechanisms/cytoskeletal-dynamics)
• [Actin Polymerization](/mechanisms/actin-polymerization)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [FUS Gene](/genes/fus)
• [SOD1 Gene](/genes/sod1)
• [C9orf72 Gene](/genes/c9orf72)
• [Profilin-1 Protein](/proteins/profilin-1-protein)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving PFN1 — Profilin 1 discovered through SciDEX knowledge graph analysis: